us you, and today. with you everyone, being morning, thank Thank and for Denis, good
accelerate changes. a the in full what global on present where are of accomplished, a I said financial in clear we quarterly review of that than resemblance joined less It past, commercialization have first especially a recognize the and products as to of and and fully X performance, Theratechnologies I icon. with was our fourth to quarter year would identify my will more and of of thanks patient education year CEO, The our much to little levers business of to our became the the progression our of that medicines. the success days future I not, believe quickly results I also model. our of that XX during April, company COVID-XX business performance call Last of XXXX needed the potential. were XX HIV. model both year unique the I we company required undergone for the establish pandemic significant properly has the realized we continued and the challenged As reflect investment HCP changes or benefits take to optimize to our to proud our the EGRIFTA ago required sales Trogarzo, have
of environment. adapt to initiatives. upon second evidence the the is real-world to virtual guidelines and pandemic patient of in the year, implemented the business improve were our our building inform marketing by and HIV digital advance such, to As outcomes half living goal and model changes increase with in care The people
from the worsening that one we about of HIV a pandemic metabolic both conversations launched and is patients patient's doctors disease. telemedicine symptom tools to fat treatment condition, particularly our with initiate COVID-XX it medicines urgency as latest meaningful condition, treatment an as to better a HCPs and have visceral allow their and to serious compliance. which consultations understand our education added message option This important differentiate visceral maintain to their program lifestyle to links the and We the instance, during to information, For between supports treat increased, and severity. to patients fat
a As maintaining HCPs undetectable for the deployed Trogarzo, patients have and importance virtual by aimed and load. events an similar we on viral approach developing of tools at educating online
with HIV, a uncontrolled living have increased implications patients can morbidity viremic and overall load huge health, their people are For detectable viral at of HIV-associated risk these mortality. on and
for V competition. developing long-acting called In their new create we help viral program urgency profile selling exhausted benefit Trogarzo's to to multidrug-resistant with disease. people we here as to sense a load identify the treat equals HCPs for options fact, a a to branded condition. HIV keep We're equals treat V also which and uncontrolled vulnerability, have tools that goal is doctors of their key stands versus The
a HIV activation leverages drive our detectable high Our a media to lipodystrophy prevalence patient Furthermore, and self-identification liaison in new of or team to patient community influencers to load. patients at performs outreach new digital and risk identify social viral areas approach case in digital managers help request.
own I mentioned empower superior and to lead condition, wish their have changes we accomplished just been HCPs better improvement without result, these, more patients to and our teams. the business not as in HCPs at well-integrated a will now And with environment. The cross-functionality With to outcome. between could interaction commercial and out a is patients ultimately, virtual our efficient sales, a medical and to reaching far marketing more which
during HIV have this many interactions care treat multidrug-resistant face-to-face space to the challenging to it trigger pandemic, more understood like resources not made having patients and limitations may physicians is well other growth. However, sales robust health the urgency in community, change. to The to companies lack in recognize a
been In through to a patient Trogarzo. with treatment a Trogarzo, the we on clinic. initiate that order at must In be screened hospital or getting a fact, a main pandemic has experienced barrier initiated patients have
stay a to home with emerged to and at start the the overwhelmed treatment. impeding asked patient's while -- Europe thereby been during paradigm cases, Unsurprisingly, have patients are most in However, hospitals with similar delaying, in COVID-XX, year. ability
as get thereby of countries the additional to ability Trogarzo we launch impact on European in from is dossier our strong COVID-XX to key, medicines As the ready strict countries, of for and Patient imposed our saw as in our measures delay wish identification of review we is outside were lifted. lockdown lockdown to impeding patients build Trogarzo, many soon a base Germany. regulatory
we other European will work to adapt obtaining new business to ahead, improving in countries, we'll pandemic-imposed and continue Trogarzo key infrastructure focused remain on and sales to Looking for towards reimbursement U.S. European our this environment.
we financing before Now upon me the exercise pipeline, turning last to month. touch let the completed
a closed As offering January activities, to we fund million initiatives needs. of on our commercial announced XX, help capital $XX approximately working and R&D bought-deal
tremendous enhance HIV our execute have markets clinical competitive invest potential HIV to adequate to to position we we clinical current progress have X late-stage areas. marketing recent a Moreover, hold We believe continue as that we quickly opportunities that study ensures initiate and firmly Strengthening to offering, ago, and drivers our prove business the management to oncology significant positioned significant towards medicines The going disease objectives life a to support continue much programs we're further our our programs, in initiatives to we with shareholders. the us in the to offering potential, acknowledge now for successfully assets our our serve. company we we value and the strategy commercial these entering to programs the moments our a on NASH. well and value be the study resources pipeline pipeline mentioned are larger niche has through in huge initiation cycle forward. helps position company build identified XXXX, the that cash in and franchise. for look significant of our As our our XXXX Phase will for the of inflection January build offering for that point I Through HIV a
Designation excited we its we objectives prospects. ago, of announced In Our sortilin-positive drug oncology, agent few conjugate, our cancers. our very for THXXXX treatment the lead Fast pipeline single important is about received are the of from strategically a as a the part FDA all peptide weeks value-driving and Track as
need. is and biomarkers; than designed of As the the completed a a the which the The is frequent of drugs review, accelerated opens Track for per medical entire assist the needed met; design completed process plan support the Application, frequent indication development It sections trial our a expedite get Track eligibility execution including: relevant treat an clinical until have is facilitate unmet the new a of is trial, and of such with application Phase data purpose NDA drugs To to global written and and reception website, serious the patient submit things with are with Fast of proposed collection can remarkable Designation well-recognized drug Fast means of criteria FDA's use that data. approval ensure be the the conditions The review appropriate more FDA's contracted can drug's Designation the communication to priority important to review, as the the Drug of to to to earlier. fill more discuss to solely CRO. I the approval; Track door to clinical wait company such development based particularly broad drug rather have many a meetings the FDA about and from reviewed. we for New before rolling finally, benefits, the on preclinical obtained the FDA the Fast NDA, if and
of dose-escalating XXXX. only could part this our results received of pipeline. in that treatment our program, is provide May Through we area cancer our SORTX+ unmet a a FDA believe that an innovative bring may from be we to technology, NASH we There But the you treated. had of III We announced opportunity end On change Phase clinical way the as also for trial NASH. that the expect an letter Study X, for high to the we need. element have deliver January the peptide trial fit-for-purpose position developed X is is we around tesamorelin the know, treatment for the of to which of Proceed believe of a to another
the enter trial. finding discuss with of their a to As FDA's aligned we agency the Phase development we III per ensure with for our protocol have fully the to requested this expectations recommendation, meeting that
plan also a discuss the that European to we with can in have ensure to We program territories. both authorities common
trial of calendar this year. Our the third III initiate quarter the Phase goal in remains to
study formulation will of It for a even the In formulation XXXX. me, taking supplemental FX pipeline, of clear our License that tesamorelin well. is used the into expect NASH in addition We in to pen the FX be that with development file new Application is to to account progressing Biologics the injector still the conjunction early indication, a continue also not to the we multi-dose with to way that the physicians formulation and management of push the in potential has for an Furthermore, the injector fat. third progress TaiMed our make multi-dose visceral of change quarter of IV Trogarzo Biologics, at with expect look pen completed to indication in be the XXXX. agreement evaluating
administration an Following and planning to of study of begin that, to XXXX. TaiMed expected evaluate intramuscular Theratechnologies That is Trogarzo. for in the are first half method
were pipeline and Our strategic XXXX or objectives exceeded on prepare ambitious of for have front the in Theratechnologies. been the advance future and to met the
now fourth results. full to and ahead. quarter Let's Philippe please XXXX turn for Philippe, go
